Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
Written by Black Hot Fire Network on May 4, 2023
- Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology.
- Products from Adalvo slated for near- to mid-term launches, with four out of six anticipated to be first-to-market
- Sandoz continues to expand patient access to much-needed medications, drive patient savings, and ensure the sustainability of healthcare systems worldwide
Basel, May 4, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that it has signed a distribution . . .
